ODDITY: Beauty Tech Company’s Product Marketing Based on Artificial Intelligence Claims Called into Question

Harrow: VEVYE Excluded from Stand-Alone Part D Plans in 2025, Amid Company’s Claims of ‘Market Access Win’ in Medicare

VEVYE, a dry eye disease drug marketed by Harrow (HROW), doesn’t appear to be covered by any Medicare Part D prescription drug plans in 2025, despite the ophthalmic health care company advertising...

Medicare Formularies Shift to Covering Generic Mifepristone Instead of Branded Korlym for 2025

Corcept’s flagship product Korlym (mifepristone) has been removed from the preferred drug lists, or formularies, of nine out of 12 national prescription drug plans under Medicare Part D in 2025, a...

Dave: Company Voluntarily Eliminates Optional Tips and Express Fees for ExtraCash Product, Online Reviews Reveal Some Customers’ Negative View of New Fee Structure

The Department of Justice filed an amended complaint against Dave (DAVE) late last month, taking over the case from the Federal Trade Commission. The amended complaint seeks civil penalties and names...